ADCE-B05 / Adcendo - LARVOL DELTA

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline (Adcendo Press Release) - "Proceeds from the fundraise will be used to support Adcendo through multiple upcoming key clinical milestones from the Company’s first- and best-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC) Phase I Tiffany-01 Cohort expansion study in multiple high unmet need tumor indications, the ADCE-D01 (uPARAP) ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other cancers of mesenchymal origin, and the ADCE-B05 (undisclosed target) dose escalation study in squamous cell carcinomas."

Financing • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma

First patient dosed in the First-in-human Phase 1 trial of ADCE-B05 in the US. (PRNewswire) - "ADCE-B05 is a first-in-class ADC directed against a novel, undisclosed ADC target overexpressed in multiple tumors of squamous origin. ADCE-B05 is being evaluated as monotherapy in a first-in-human Phase I (NCT07362888) clinical trial enrolling patients across US and Australian sites."

First-in-human • Trial status • Solid Tumor • Squamous Cell Carcinoma

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Adcendo ApS | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Not yet recruiting | Sponsor: Adcendo ApS

First-in-human • New P1 trial • Oncology • Solid Tumor

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline (PRNewswire) - "Adcendo...announced the successful closing of an oversubscribed $135 million Series B financing round. Proceeds from the fundraise will be used to advance, broaden, and accelerate the development of the Company's first-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programs. The financing round was led by TCGX, with participation from new investors TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, as well as all existing investors, including RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital."

Financing • Oncology